GlassScriptPhysician profile
Erick Hernandez
NPI 1609803261
$12,055.36
in general payments reported to CMS, 2019-2025
28 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 82% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,356 · 2020: $2,334 · 2021: $812 · 2022: $1,453 · 2023: $1,296 · 2024: $766 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.39 |
| Education | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $7,232.43 | 2019-2023 | Cholbam |
| Janssen Biotech, INC. | $730.52 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $700.56 | 2019-2025 | |
| Genzyme Corporation | $507.62 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $492.46 | 2021-2025 | Gattex, Eohilia, Vpriv |
| Janssen Scientific Affairs, LLC | $310.60 | 2020-2023 | Stelara |
| Albireo Pharma, INC. | $260.21 | 2022-2023 | Bylvay |
| Mirum Pharmaceuticals, INC. | $252.64 | 2023-2025 | Livmarli, Cholbam, Chenodal |
| Ipsen Biopharmaceuticals, INC | $223.29 | 2024-2025 | Bylvay |
| Qol Medical, LLC | $221.97 | 2019-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $196.14 | 2022-2024 | Dupixent |
| Medtronic, INC. | $150.48 | 2022 | |
| Intrabio INC | $145.94 | 2025 | Aqneursa |
| Tg Therapeutics, INC. | $116.47 | 2023 | |
| Alexion Pharmaceuticals, INC. | $84.40 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $80.08 | 2021-2023 | |
| Amgen INC. | $75.22 | 2020-2021 | |
| Orphalan INC | $67.87 | 2024 | Cuvrior |
| Organon LLC | $46.70 | 2021-2024 | |
| Eton Pharmaceuticals, INC. | $24.17 | 2025 | Nitisinone, Betaine Anhydrous, Galzin |
| Mauna Kea Technologies, INC. | $23.46 | 2025 | |
| Celltrion USA INC. | $21.00 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $18.25 | 2022 | |
| Amryt Pharma Holdings LTD | $17.73 | 2021 | |
| Aimmune Therapeutics, INC. | $14.22 | 2025 | Zenpep |
| Phadia US INC. | $14.04 | 2019 | |
| Olympus America INC. | $13.69 | 2025 | Endoclot Phs |
| Laborie Medical Technologies Corp. | $13.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.